Umeclidinium

Details

Files

Generic Name:

Umeclidinium

Project Status:

Complete

Therapeutic Area:

Chronic obstructive pulmonary disease

Manufacturer:

GlaxoSmithKline Inc.

Call for patient/clinician input open:

January 14, 2015

Brand Name:

Incruse Ellipta

Project Line:

Reimbursement Review

Project Number:

SR0422-000

Call for patient/clinician input closed:

March 5, 2015

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Chronic Obstructive Pulmonary Disease (COPD)

Recommendation Type:

List with criteria/condition

Final Recommendation:

September 18, 2015

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Clinical Report View PDF

Pharmcoeconomic Report View PDF

Last Updated : March 4, 2015